Cargando…
Recombinant Factor VIII Fc Inhibits B Cell Activation via Engagement of the FcγRIIB Receptor
The development of neutralizing antibodies (inhibitors) against factor VIII (FVIII) is a major complication of hemophilia A treatment. The sole clinical therapy to restore FVIII tolerance in patients with inhibitors remains immune tolerance induction (ITI) which is expensive, difficult to administer...
Autores principales: | Georgescu, Maria T., Moorehead, Paul C., Liu, Tongyao, Dumont, Jennifer, Scott, David W., Hough, Christine, Lillicrap, David |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7025534/ https://www.ncbi.nlm.nih.gov/pubmed/32117285 http://dx.doi.org/10.3389/fimmu.2020.00138 |
Ejemplares similares
-
The Complex Association of FcγRIIb With Autoimmune Susceptibility
por: Verbeek, J. Sjef, et al.
Publicado: (2019) -
IgG-Independent Co-aggregation of FcεRI and FcγRIIB Results in LYN- and SHIP1-Dependent Tyrosine Phosphorylation of FcγRIIB in Murine Bone Marrow-Derived Mast Cells
por: Gast, Mathias, et al.
Publicado: (2018) -
Targeting the Antibody Checkpoints to Enhance Cancer Immunotherapy–Focus on FcγRIIB
por: Teige, Ingrid, et al.
Publicado: (2019) -
Regulation of Monoclonal Antibody Immunotherapy by FcγRIIB
por: Stopforth, Richard J., et al.
Publicado: (2016) -
FcγRIIB-I232T polymorphic change allosterically suppresses ligand binding
por: Hu, Wei, et al.
Publicado: (2019)